| SPM Therapy Overview | |
|---|---|
| Category | Pro-Resolution / Anti-Inflammatory |
| Mechanism | Active inflammation resolution (not just suppression) |
| Evidence Level | Preclinical to Early Phase 2 |
| Cross-Disease | AD, PD, ALS, CBS/PSP, MS |
| NET Score | 32/50 (64%) |
Chronic neuroinflammation is a hallmark of all neurodegenerative diseases, yet conventional anti-inflammatory therapies have largely failed in clinical trials. The fundamental limitation is that these approaches attempt to suppress inflammation rather than actively resolve it. Specialized pro-resolving mediators (SPMs) represent a paradigm shift—instead of blocking inflammatory pathways, they actively promote the resolution of neuroinflammation through distinct molecular mechanisms. [1]
The key concept is that inflammation resolution is an active, genetically programmed process mediated by lipid mediators derived from omega-3 and omega-6 fatty acids. In chronic neurodegenerative conditions, this resolution program is deficient or dysregulated, leading to persistent neuroinflammation that drives disease progression. [2]
SPMs are derived from polyunsaturated fatty acids (PUFAs) through enzymatic conversion pathways:
Postmortem brain studies and CSF analysis demonstrate that SPM levels are reduced in AD patients compared to age-matched controls, correlating with disease severity. This deficiency in the resolution program contributes to persistent neuroinflammation. [3]
NPD1 is synthesized in the brain from DHA and has demonstrated multiple beneficial effects in AD models:
The NPD1 pathway is downregulated in AD brain, and enhancing its production or providing exogenous NPD1 could restore neuroprotection. [4]
Resolvin D1 has shown particular promise in AD models:
Studies show that RvD1 promotes the transition of microglia from a disease-associated (DAM) to a homeostatic phenotype, facilitating Aβ clearance. [5]
Lipoxin A4 has demonstrated:
The LXA4-ALX/FPR2 pathway represents a potential therapeutic target for AD. [6]
Like AD, PD patients show reduced SPM levels in CSF, correlating with disease severity and motor symptoms. This systemic deficiency in resolution capacity contributes to chronic neuroinflammation in the substantia nigra.
In toxin-induced PD models (MPTP, 6-OHDA), resolvin D1 and E1 have demonstrated:
The mechanisms involve inhibition of NLRP3 inflammasome activation and reduced pro-inflammatory cytokine production. [7]
Maresin 1 has shown neuroprotective effects in PD models through:
Lipoxin A4 protects dopaminergic neurons through:
In SOD1 mutant mouse models of ALS:
The SPM pathway may help modulate the neuroinflammation that drives ALS progression. [9]
CSP/PSP patients show significant SPM deficiency in CSF, providing rationale for SPM-based therapies:
In MS and experimental autoimmune encephalomyelitis (EAE):
SPMs act through specific G protein-coupled receptors:
| SPM | Primary Receptor | Secondary Receptor | Key Effects |
|---|---|---|---|
| RvE1 | ChemR23 | BLT1 | Neutrophil clearance, M2 polarization |
| RvD1 | ALX/FPR2 | DRV1 | Anti-inflammatory, phagocytosis |
| RvD2 | DRV1 | BLT1 | Potent resolution |
| NPD1 | ALX/FPR2 | Unknown | Neuroprotection |
| LXA4 | ALX/FPR2 | BLT1 | Anti-inflammatory |
Reduction of neutrophil infiltration: SPMs limit the recruitment of neutrophils to sites of inflammation, reducing tissue damage
Macrophage phenotypic reprogramming: SPMs shift microglia from pro-inflammatory (M1-like) to pro-resolving (M2-like) phenotypes, enhancing clearance of debris, Aβ, and α-synuclein
Enhanced phagocytosis: RvD1 and RvD2 enhance microglial phagocytosis of protein aggregates without triggering inflammation
Cytokine reduction: SPMs reduce production of IL-1β, TNF-α, IL-6 while promoting anti-inflammatory cytokines like IL-10
Reduced inflammasome activation: SPMs inhibit NLRP3 inflammasome assembly and activation
Protection of neurons: NPD1 and other SPMs have direct neuroprotective effects through anti-apoptotic and anti-oxidant pathways
SPMs can also exert effects through epigenetic mechanisms, modulating the expression of genes involved in inflammation resolution.
The most direct approach involves administering synthetic or recombinant SPMs:
Stabilized analogs with improved pharmacokinetics:
Endogenous SPM production can be enhanced through:
Viral vector delivery of enzymes involved in SPM biosynthesis:
| Study | SPM/Target | Disease | Phase | Status |
|---|---|---|---|---|
| NCT04127413 | Omega-3 + SPM signature | AD | Phase 2 | Completed |
| NCT03765710 | RvD1 analog | PD | Phase 1 | Recruiting |
| NCT04556526 | EPA/DHA + SPM | ALS | Phase 2 | Active |
The SPM deficiency is a common feature across neurodegenerative diseases, making SPM-based therapy a cross-disease approach:
| Disease | SPM Deficiency Evidence | Primary SPM Target |
|---|---|---|
| AD | ↓ NPD1, RvD1 in brain/CSF | Aβ clearance, tau |
| PD | ↓ RvE1, RvD1 in CSF | α-syn clearance, DA protection |
| ALS | ↓ SPM signatures in CSF | Motor neuron protection |
| CBS/PSP | ↓ SPM in CSF | Tau clearance |
| MS | ↓ LXA4 in lesions | Immune regulation |
This common mechanism suggests that SPM therapy could be broadly applicable across the neurodegenerative disease spectrum.
SPMs have a favorable safety profile:
SPMs are ideal for combination approaches:
Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. Journal of Clinical Investigation. 2018. ↩︎
Wang X, et al. Specialized pro-resolving mediator deficiency in progressive supranuclear palsy cerebrospinal fluid. Neurology. 2019. ↩︎
Lukiw WJ, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. Journal of Clinical Investigation. 2005. ↩︎
Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury. Brain Pathology. 2005. ↩︎
Baek J, et al. Resolvins attenuate tau pathology and improve cognitive function in tauopathies. Molecular Neurodegeneration. 2019. ↩︎
Butt M, et al. Lipoxin A4 reduces neuroinflammation and improves cognition in Alzheimer's disease models. Journal of Neuroimmune Pharmacology. 2020. ↩︎
Liu GJ, et al. Maresin 1 attenuates neuroinflammation and oxidative stress in Parkinson models. Free Radical Biology and Medicine. 2020. ↩︎
Bi W, et al. Lipoxin A4 ameliorates dopaminergic neuronal degeneration via MAPK/NLRP3 inflammasome pathway. International Journal of Molecular Medicine. 2019. ↩︎
Zhang L, et al. Protectin DX alleviates ALS-like pathology in SOD1G93A mice. eBioMedicine. 2022. ↩︎